RxDoctor Payments Data

Brian Chinavare, MD

Ophthalmology · Toledo, OHNPI 1568455806

Payments from drug & device makers

$798in general payments, 2019–2025

Across 20 payments — averaging $39.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$504
  • Regeneron$96
  • ANI Pharmaceuticals, Inc.$66
  • AbbVie$59
  • Alcon$40
  • Bausch & Lomb Americas Inc.$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$78198%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 40th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$356,121
Medicare patients
1,204
Services billed
5,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost99$32,951
RestasisCyclosporine35$30,700
Prednisolone Acetate523$26,942
XiidraLifitegrast15$20,251
Timolol Maleate1,034$12,345
MoxifloxacinMoxifloxacin Hcl292$11,430
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$10,528
Latanoprost1,136$9,423
Brimonidine Tartrate319$8,907
Cyclosporine15$8,607
CombiganBrimonidine Tartrate/Timolol13$3,816
Dorzolamide Hcl177$3,593
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat92$1,790
ErythromycinErythromycin Base182$1,780
Travoprost24$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$59$67,466147 claims
Bausch & Lomb Americas Inc.Xiidra$18$20,25115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →